Catheter Precision, Inc. 8K

Catheter Precision, Inc. reported strong Q1 2026 revenue growth and a sharply reduced net loss while completing and rapidly scaling its transformative acquisition of aviation platform Flyte, positioning the company as a diversified dual‑segment growth business.

On May 18, 2026, Catheter Precision, Inc. announced its first quarter 2026 results, reporting a 200% year-over-year revenue increase to $432,000, a substantial reduction in net loss to $1.7 million from $4.0 million in Q1 2025, and the completion and rapid scaling of its transformative acquisition of Flyte, a technology-enabled regional air mobility platform. The company highlighted strong growth and clinical validation in its core medical device electrophysiology business, including expanded global adoption of its VIVO and LockeT products across 15 countries and new peer‑reviewed publications, while the newly acquired Flyte segment quickly ramped its fleet from 1 to 3 aircraft with additional jets expected, achieved a $200,000 monthly revenue run rate within 22 days of post-acquisition operations, and began pursuing FAA approvals for expansion into international markets such as Toronto and the Bahamas. Management emphasized that the combined medical device and aviation operations position Catheter Precision as a dual‑engine growth platform with diversified revenue streams, improved operating leverage, and scalable expansion potential across both healthcare and mobility markets.

Filing Facts

CIK

1716621

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-017612

Alert Tier

7